213
Views
5
CrossRef citations to date
0
Altmetric
Review

Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports

&
Pages 547-558 | Received 28 Jan 2021, Accepted 15 Mar 2021, Published online: 30 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

José María Prieto González & Carlos Vila Silván. (2021) Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials. Expert Review of Neurotherapeutics 21:7, pages 755-778.
Read now

Articles from other publishers (4)

Ibtisam A. Al Thubaiti, Mona M. AlKhawajah, Norah Al Fugham, Dema A. Alissa, Ahmed H. Al-Jedai, Yaser M. Al Malik, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Bedor A. Al-Omari, Hessa S. AlOtaibi, Rumaiza H. Al Yafeai, Mohammed A. Babakkor, Reem F. Bunyan, Edward J. Cupler, Mohammed Hakami, Hanaa M. Kedah, Seraj Makkawi, Leena H. Saeed, Jameelah A. Saeedi, Eslam Shosha & Mohammed A. Al Jumah. (2023) Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Symptom Management and Vaccination. Clinical and Translational Neuroscience 7:1, pages 6.
Crossref
Ivan A. RossIvan A. Ross. 2023. Plant-Based Therapeutics, Volume 1. Plant-Based Therapeutics, Volume 1 249 301 .
Armando Creta, Luana Gilio, Diego Centonze & Roberta Fantozzi. (2022) Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis. Neurodegenerative Disease Management 12:4, pages 195-201.
Crossref
Andrew Chan & Carlos Vila Silván. (2022) Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.